エプチフィバチド市場：タイプ別、用途別 - 2024年～2030年の世界予測

エプチフィバチド市場規模は2023年に3億8,982万米ドルと推定され、2024年には4億1,106万米ドルに達し、CAGR 5.76%で2030年には5億7,729万米ドルに達すると予測されています。

エプチフィバチドは、南東部ピグミーガラガラヘビ（Sistrurus miliarius barbouri）の毒に含まれるタンパク質に由来する環状ヘプタペプチドです。エプチフィバチドは、血栓予防に重要な役割を果たす血小板凝集抑制剤であり、経皮的冠動脈形成術（PCI）の際に広く使用されています。心血管疾患の有病率の大幅な上昇と、心臓疾患にかかりやすい高齢者人口の増加が、エプチフィバチドの世界の必要性を後押ししています。経皮的冠動脈インターベンション（PCI）手技の進歩が、エプチフィバチドの利用における技術革新を後押ししています。有利な償還政策とヘルスケア支出の増加も市場拡大に大きく貢献しています。成長の見込みはあるもの、出血リスクなどエプチフィバチドに関連する重大な副作用プロファイルが、市場での採用を妨げる可能性があります。また、厳しい規制基準への準拠も市場拡大の大きな課題となっています。さらに、ドラッグ製剤やドラッグデリバリー技術の継続的な進歩も、潜在的な開発・成長分野にスポットライトを当てています。エプチフィバチドと他の抗血小板薬との相乗的な組み合わせを模索する継続的な研究開発の取り組みは、市場浸透のための新たな道を切り開く可能性があります。

タイプ急性期投与には2mg/ml製剤の選好が高まる

エプチフィバチドの0.75mg/ml製剤は、一般的に一定期間の持続点滴に使用され、多くの場合ボーラス投与から開始し、その後維持投与を行う。0.75mg/mlは、体重や腎機能などの特定の臨床的要因によって低用量が必要とされる患者に特に適しています。0.75mg/ml製剤は正確な用量調節が可能であり、抗血小板効果の漸増または漸減が必要な治療プロトコールによく用いられます。エプチフィバチドの2mg/ml製剤は、特に経皮的冠動脈インターベンション（PCI）中やその直後など、迅速な血小板抑制を必要とする高ストレス場面での急性期投与用に設計されています。高濃度であるため、ボーラス投与後、臨床反応や患者の状態に応じて調節可能な維持点滴を迅速に行うことができます。

応用心筋梗塞における多様な応用範囲

エプチフィバチドは、治療レジメンの一環として投与され、血栓のさらなる形成を防ぐことにより、その後の心血管イベントのリスクを低減します。心筋梗塞症例におけるエプチフィバチドの必要性に基づく選好は、経皮的冠動脈インターベンション（PCI）中の患者の転帰を向上させる効果に由来します。不安定狭心症は、心臓への血流が減少することによって起こる胸痛の一種ですが、これもエプチフィバチドの重要な応用分野です。MIと同様、エプチフィバチドの役割は血小板凝集を防ぐことにあり、心臓発作のリスクを軽減します。

地域別の洞察

南北アメリカ、特に米国とカナダでは、エプチフィバチドの使用は高度なヘルスケアインフラと心血管疾患の高い有病率に大きく影響されています。米国とカナダでは、特許の崖によりジェネリック医薬品の利用が増加し、顧客の購買行動に影響を与えています。欧州連合（EU）では、人口の高齢化とそれに伴う心血管疾患の増加により、エプチフィバチドに対する需要が高いです。欧州諸国は医療制度が充実しており、医療費削減への取り組みがエプチフィバチドの市場力学に影響を与えています。医療インフラが比較的整備され、所得水準が高い中東地域では、エプチフィバチドを含む先進的な治療オプションに対する需要が高まっています。限られたヘルスケア施設と手頃な価格の問題により、アフリカ市場ではエプチフィバチドの採用が制約されています。アジア太平洋地域では、中国、日本、インドといった国々が、人口の多さと心血管疾患の増加により、エプチフィバチド市場において極めて重要な位置を占めています。中国市場は、ヘルスケアを改善し、エプチフィバチドを含む医薬品の現地生産を促進する政府のイニシアティブの影響を受け、急速に成長しています。先進的なヘルスケアシステムを持つ日本は、革新的な治療ソリューションに注目し、引き続き重要な消費国です。インド市場の特徴は、ヘルスケアに対する意識の高まりと価格の安さであり、ジェネリック医薬品がAPAC地域の市場成長に貢献しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、エプチフィバチド市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、エプチフィバチド市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.エプチフィバチド市場の市場規模および予測は？

2.エプチフィバチド市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.エプチフィバチド市場の技術動向と規制枠組みは？

4.エプチフィバチド市場における主要ベンダーの市場シェアは？

5.エプチフィバチド市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 心血管疾患の罹患率の上昇と心臓疾患にかかりやすい高齢者人口の増加
    • 経皮的冠動脈インターベンション（PCI）技術の継続的な進歩
    • ヘルスケア費の増加と有利な償還政策
  • 抑制要因
    • エプチフィバチドの使用に伴う副作用と安全上のリスク
  • 機会
    • 薬剤の処方と投与技術の継続的な進歩
    • 他の抗血小板薬との相乗効果を追求する研究開発活動を継続中
  • 課題
    • 厳格な規制基準への準拠
• 市場セグメンテーション分析
  • タイプ：急性投与用の2mg/ml製剤の好ましさが高まっている
  • 応用：心筋梗塞における多様な応用範囲
• 市場ディスラプション分析
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 価格分析
• 技術分析
• 特許分析
• 貿易分析
• 規制枠組みの分析

第6章 エプチフィバチド市場：タイプ別

• 0.75mg/mlエプチフィバチド
• 2mg/mlエプチフィバチド

第7章 エプチフィバチド市場：用途別

• 心筋梗塞
• 不安定狭心症

第8章 南北アメリカのエプチフィバチド市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋のエプチフィバチド市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのエプチフィバチド市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • 抗血小板療法は致命的な脳出血患者の転帰を改善する可能性がある、と新たな研究が明らかに
  • カナダの病院が重要な医薬品の不足に悩まされる中、ジュノ・ファーマシューティカルズがエプチフィバチドの輸入承認を取得
• 戦略分析と提言

第12章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. EPTIFIBATIDE MARKET RESEARCH PROCESS
• FIGURE 2. EPTIFIBATIDE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL EPTIFIBATIDE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. EPTIFIBATIDE MARKET DYNAMICS
• FIGURE 7. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 12. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 14. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EPTIFIBATIDE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 20. EPTIFIBATIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. EPTIFIBATIDE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL EPTIFIBATIDE MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL EPTIFIBATIDE MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL EPTIFIBATIDE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 0.75MG/ML EPTIFIBATIDE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 0.75MG/ML EPTIFIBATIDE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 2MG/ML EPTIFIBATIDE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL EPTIFIBATIDE MARKET SIZE, BY 2MG/ML EPTIFIBATIDE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL EPTIFIBATIDE MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL EPTIFIBATIDE MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL EPTIFIBATIDE MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL EPTIFIBATIDE MARKET SIZE, BY UNSTABLE ANGINA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. AMERICAS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 20. AMERICAS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 21. AMERICAS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 22. AMERICAS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 23. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 24. AMERICAS EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 25. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 26. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 27. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 28. ARGENTINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 29. BRAZIL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 30. BRAZIL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 31. BRAZIL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 32. BRAZIL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 33. CANADA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 34. CANADA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 35. CANADA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 36. CANADA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 37. MEXICO EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 38. MEXICO EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 39. MEXICO EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 40. MEXICO EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 41. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 42. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 43. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 44. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 45. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 46. UNITED STATES EPTIFIBATIDE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 48. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 50. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 52. ASIA-PACIFIC EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 53. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 54. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 55. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 56. AUSTRALIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 57. CHINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 58. CHINA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 59. CHINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 60. CHINA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 61. INDIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 62. INDIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 63. INDIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 64. INDIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 65. INDONESIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 66. INDONESIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 67. INDONESIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 68. INDONESIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 69. JAPAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 70. JAPAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 71. JAPAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 72. JAPAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 73. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 74. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 75. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. MALAYSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 78. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 79. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 80. PHILIPPINES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 81. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 82. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 83. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. SINGAPORE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 86. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. SOUTH KOREA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. TAIWAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 90. TAIWAN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 91. TAIWAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 92. TAIWAN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 93. THAILAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 94. THAILAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 95. THAILAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. THAILAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. VIETNAM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 98. VIETNAM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 99. VIETNAM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. VIETNAM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA EPTIFIBATIDE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 107. DENMARK EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 108. DENMARK EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 109. DENMARK EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 110. DENMARK EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 111. EGYPT EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 112. EGYPT EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 113. EGYPT EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 114. EGYPT EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 115. FINLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 116. FINLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 117. FINLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 118. FINLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 119. FRANCE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 120. FRANCE EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 121. FRANCE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 122. FRANCE EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 123. GERMANY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 124. GERMANY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 125. GERMANY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 126. GERMANY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 127. ISRAEL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 128. ISRAEL EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 129. ISRAEL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 130. ISRAEL EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 131. ITALY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 132. ITALY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 133. ITALY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 134. ITALY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 135. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 136. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 137. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. NETHERLANDS EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. NIGERIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 140. NIGERIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 141. NIGERIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 142. NIGERIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 143. NORWAY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 144. NORWAY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 145. NORWAY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 146. NORWAY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 147. POLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 148. POLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 149. POLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. POLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. QATAR EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 152. QATAR EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 153. QATAR EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 154. QATAR EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 155. RUSSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 156. RUSSIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 157. RUSSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 158. RUSSIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 160. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 162. SAUDI ARABIA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 164. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 166. SOUTH AFRICA EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 167. SPAIN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 168. SPAIN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 169. SPAIN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. SPAIN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. SWEDEN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 172. SWEDEN EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 173. SWEDEN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. SWEDEN EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 176. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 177. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 178. SWITZERLAND EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 179. TURKEY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. TURKEY EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. TURKEY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 182. TURKEY EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 188. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 190. UNITED KINGDOM EPTIFIBATIDE MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 191. EPTIFIBATIDE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. EPTIFIBATIDE MARKET, FPNV POSITIONING MATRIX, 2023

[184 Pages Report] The Eptifibatide Market size was estimated at USD 389.82 million in 2023 and expected to reach USD 411.06 million in 2024, at a CAGR 5.76% to reach USD 577.29 million by 2030.

Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Eptifibatide is a platelet aggregation inhibitor playing a significant role in preventing blood clots and is widely used during percutaneous coronary intervention (PCI) procedures. The significant rise in prevalence of cardiovascular diseases and growing elderly population, more prone to cardiac conditions, drive the necessity of the Eptifibatide worldwide. The advancements in percutaneous coronary intervention (PCI) techniques drive the innovation in the utilization of Eptifibatide. The favorable reimbursement policies and increased healthcare expenditure also significantly contribute to market expansion. Despite the growth prospects, significant side effect profiles associated with Eptifibatide, such as bleeding risks, may hinder its adoption in the market arena. The compliance with stringent regulatory standards also poses a substantial challenge for the market expansion. Moreover, continuous advancements in drug formulation and delivery techniques also spotlight potential areas for development and growth. Ongoing R&D initiatives to explore synergistic combinations of Eptifibatide with other antiplatelet agents can pave new paths for product penetration in the market space.

Type: Increasing preference of 2 mg/ml formulation for acute administration

The 0.75mg/ml of Eptifibatide is generally used for continuous infusion over a period, often starting with a bolus dose followed by maintenance dosing. 0.75mg/ml is particularly suited for patients that require a lower dose due to specific clinical factors such as weight or renal function. The 0.75mg/ml solution allows for precise dosing adjustments and is commonly preferred in treatment protocols that necessitate gradual escalation or reduction of the antiplatelet effect. The Eptifibatide's 2mg/ml formulation is designed for acute administration, particularly in high-stress scenarios requiring rapid platelet inhibition, such as during or immediately after percutaneous coronary interventions (PCI). The higher concentration enables quicker administration of a bolus dose, followed by a maintenance infusion that can be adjusted based on clinical response and patient condition.

Application: Diverse scope of applications in myocardial infarction

Eptifibatide is administered as part of the therapeutic regimen to prevent further clot formation, thus reducing the risk of subsequent cardiovascular events. The need-based preference for Eptifibatide in myocardial infarction cases stems from its effectiveness in enhancing patient outcomes during percutaneous coronary intervention (PCI). Unstable Angina, a type of chest pain caused by reduced blood flow to the heart, is another critical application area for Eptifibatide. Similar to MI, Eptifibatide's role is centered on preventing platelet aggregation, thus mitigating the risk of a heart attack.

Regional Insights

In the Americas, particularly the United States and Canada, the usage of Eptifibatide is significantly influenced by the advanced healthcare infrastructure and high prevalence of cardiovascular diseases. In the United States and Canada, patent cliffs have led to increased availability of generic versions, impacting customers' purchasing behaviors in the region. The European Union (EU) exhibits a high demand for Eptifibatide largely due to the aging population and the consequent rise in cardiovascular diseases. European countries have a robust healthcare system and initiatives to reduce healthcare expenditure, which influences the Eptifibatide market dynamics. Due to its relatively better healthcare infrastructure and higher income levels, the Middle East region shows a growing demand for advanced therapeutic options including Eptifibatide. Limited healthcare facilities and affordability issues constrain the African market for the adoption of eptifibatide. In the Asia Pacific region, countries such as China, Japan, and India are pivotal in the Eptifibatide market due to their large populations and increasing incidence of cardiovascular diseases. China's market is growing rapidly, influenced by government initiatives to improve healthcare and boost the local production of pharmaceuticals, including Eptifibatide. With its advanced healthcare system, Japan continues to be a significant consumer, focusing on innovative treatment solutions. India's market is characterized by growing healthcare awareness and affordability issues, with generic drugs contributing to the market growth in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Eptifibatide Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Eptifibatide Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Eptifibatide Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare, Amneal Pharmaceuticals LLC, Baxter International Inc., Eugia US LLC, GlaxoSmithKline PLC, Hybio Pharmaceutical Co., Ltd., Kensington Pharma, Merck & Co., Inc., Novetide Ltd., Sagent Pharmaceuticals, Slate Run Pharmaceuticals, Strides Pharma Canada Inc., and Taj Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Eptifibatide Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Type
  • 0.75mg/ml Eptifibatide
  • 2mg/ml Eptifibatide

• Application
  • Myocardial Infarction
  • Unstable Angina

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Eptifibatide Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Eptifibatide Market?

3. What are the technology trends and regulatory frameworks in the Eptifibatide Market?

4. What is the market share of the leading vendors in the Eptifibatide Market?

5. Which modes and strategic moves are suitable for entering the Eptifibatide Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cardiovascular diseases and growing elderly population, more prone to cardiac conditions
    • 5.1.1.2. Ongoing advancements in percutaneous coronary intervention (PCI) techniques
    • 5.1.1.3. Increased healthcare expenditure and favorable reimbursement policies
  • 5.1.2. Restraints
    • 5.1.2.1. Side effect and safety risks associated with use of Eptifibatide
  • 5.1.3. Opportunities
    • 5.1.3.1. Continuous advancements in drug formulation and delivery techniques
    • 5.1.3.2. Ongoing R&D initiatives to explore synergistic combinations with other antiplatelet agents
  • 5.1.4. Challenges
    • 5.1.4.1. Compliance with stringent regulatory standards
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing preference of 2 mg/ml formulation for acute administration
  • 5.2.2. Application: Diverse scope of applications in myocardial infarction
• 5.3. Market Disruption Analysis
• 5.4. Porter's Five Forces Analysis
  • 5.4.1. Threat of New Entrants
  • 5.4.2. Threat of Substitutes
  • 5.4.3. Bargaining Power of Customers
  • 5.4.4. Bargaining Power of Suppliers
  • 5.4.5. Industry Rivalry
• 5.5. Value Chain & Critical Path Analysis
• 5.6. Pricing Analysis
• 5.7. Technology Analysis
• 5.8. Patent Analysis
• 5.9. Trade Analysis
• 5.10. Regulatory Framework Analysis

6. Eptifibatide Market, by Type

• 6.1. Introduction
• 6.2. 0.75mg/ml Eptifibatide
• 6.3. 2mg/ml Eptifibatide

7. Eptifibatide Market, by Application

• 7.1. Introduction
• 7.2. Myocardial Infarction
• 7.3. Unstable Angina

8. Americas Eptifibatide Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Eptifibatide Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Eptifibatide Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Anti-platelet Therapy Could Help Improve Outcomes For Patients With a Deadly Form of Brain Bleed, New Study Reveals
  • 11.3.2. Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with Shortages of Critical Medicines
• 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

• 12.1. Key Company Profiles
• 12.2. Key Product Portfolio